1
|
Tanaka R, Kurihara Y, Ouchi T, Funakoshi T, Takahashi H, Arao N, Tanikawa A, Kubo A, Amagai M, Yamagami J. 064 Early Clinical Score Changes Predict Additional Treatment Necessity In Pemphigus/Pemphigoid. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
2
|
Imafuku K, Iwata H, Natsuga K, Okumura M, Kobayashi Y, Kitahata H, Kubo A, Nagayama M, Ujiie H. 197 Tissue proliferation and turnover spatially regulates tight junctions in squamous epithelia. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Tahara U, Matsui T, Atsugi T, Fukuda K, Kubo A, Amagai M. 532 Unexpected expression of hemoglobin α as an endogenous antioxidant in epidermal keratinocytes. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Shiiya C, Aoki S, Nakabayashi K, Hata K, Amagai M, Kubo A. Linear and disseminated porokeratosis in one family showing identical and independent second hits in MVD among skin lesions, respectively: a proof-of-concept study. Br J Dermatol 2021; 184:1209-1212. [PMID: 33481264 DOI: 10.1111/bjd.19824] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Revised: 01/17/2021] [Accepted: 01/18/2021] [Indexed: 12/24/2022]
Affiliation(s)
- C Shiiya
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - S Aoki
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - K Nakabayashi
- Department of Maternal-Fetal Biology, National Centre for Child Health and Development, Tokyo, Japan
| | - K Hata
- Department of Maternal-Fetal Biology, National Centre for Child Health and Development, Tokyo, Japan
| | - M Amagai
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - A Kubo
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
5
|
Agematsu A, Kamata M, Uchida H, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Tada Y, Kubo A. A case of type 1 segmental Darier disease showing widespread Blaschkoid skin lesions with p.P160L mutation in
ATP2A2. J Eur Acad Dermatol Venereol 2020; 34:e633-e635. [DOI: 10.1111/jdv.16506] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- A. Agematsu
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - M. Kamata
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - H. Uchida
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - M. Nagata
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - S. Fukaya
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - K. Hayashi
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - A. Fukuyasu
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - T. Tanaka
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - T. Ishikawa
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - T. Ohnishi
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - Y. Tada
- Department of Dermatology Teikyo University School of Medicine Tokyo Japan
| | - A. Kubo
- Department of Dermatology Keio University School of Medicine Shinjuku Japan
| |
Collapse
|
6
|
Inoue-Masuda Y, Hirai I, Yanagisawa E, Kurihara Y, Funakoshi T, Yamagami J, Amagai M, Kubo A. An adult case of X-linked chronic granulomatous disease with skin ulcer on the nose and internal canthus. J Eur Acad Dermatol Venereol 2020; 34:e388-e391. [PMID: 32043662 DOI: 10.1111/jdv.16291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Y Inoue-Masuda
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - I Hirai
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - E Yanagisawa
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - Y Kurihara
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - T Funakoshi
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - J Yamagami
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - M Amagai
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - A Kubo
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
7
|
Umegaki-Arao N, Ono N, Tanaka R, Sasaki T, Fujita H, Shiohama A, Aoki S, Amagai M, Kubo A. A nonepidermolytic keratinocytic epidermal naevus associated with a postzygotic mutation in the gene encoding epidermal growth factor receptor. Br J Dermatol 2019; 182:1303-1305. [PMID: 31745974 DOI: 10.1111/bjd.18729] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- N Umegaki-Arao
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.,Department of Dermatology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
| | - N Ono
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - R Tanaka
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - T Sasaki
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.,Center for Supercentenarian Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - H Fujita
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.,KOSÉ Endowed Program for Skin Care and Allergy Prevention, Keio University School of Medicine, Tokyo, Japan
| | - A Shiohama
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.,KOSÉ Endowed Program for Skin Care and Allergy Prevention, Keio University School of Medicine, Tokyo, Japan
| | - S Aoki
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| | - M Amagai
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.,KOSÉ Endowed Program for Skin Care and Allergy Prevention, Keio University School of Medicine, Tokyo, Japan
| | - A Kubo
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
8
|
Kunimasa K, Ito K, Yamanaka T, Fujimoto D, Mori M, Maeno K, Tomomatsu K, Tamura A, Tanaka H, Watanabe S, Teraoka S, Hataji O, Suzuki K, Hontsu S, Hara S, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N. The safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Yamaguchi T, Morikawa S, Yuko O, Asada K, Oguri T, Inui N, Ito K, Kimura T, Kunii E, Matsui T, Kubo A, Kato T, Shindo J, Tsuda T, Okuno M, Hida T, Imaizumi K. P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations with Non-Adenocartinoma Histology. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
10
|
Tanaka K, Inui N, Asada K, Abe T, Hataji O, Hayai S, Ito K, Imaizumi K, Kimura T, Kubo A, Kunii E, Murotani K, Okuno M, Oya Y, Shindoh J, Taniguchi H, Tsuda T, Yamaguchi T, Hida T, Suda T. Real-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Ito K, Murotani K, Kubo A, Kunii E, Taniguchi H, Shindo J, Asada K, Imaizumi K, Tanaka K, Inui N, Okuno M, Hataji O, Hayai S, Abe T, Kimura T, Tsuda T, Yamaguchi T, Oya Y, Yoshida T, Hida T. Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.077] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Matsumoto Y, Kawaguchi T, Sawa K, Isa S, Ando M, Tamiya A, Kubo A, Saka H, Matsumura A, Koh Y. P2.16-07 Impact of de Novo T790M on Outcome for Resected NSCLC from EGFR Mutant Cohort of Japan Molecular Epidemiology (JME) Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Kato M, Kito K, Kubo A, Takagi H. P1479Effects of preoperative exercise training on safety and exercise capacity in patients with abdominal aortic aneurysm: a meta-analysis of randomised controlled trials. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Kato
- Tokoha University, Faculty of Health Science, Shizuoka, Japan
| | - K Kito
- Shizuoka Medical Center, Department of Rehabilitation, Shizuoka, Japan
| | - A Kubo
- Tokoha University, Faculty of Health Science, Shizuoka, Japan
| | - H Takagi
- Shizuoka Medical Center, Department of Cardiovascular Surgery, Shizuoka, Japan
| |
Collapse
|
14
|
Nomura H, Kurihara Y, Saito M, Fukushima A, Shintani Y, Shiiyama R, Toshima S, Kamata A, Yamagami J, Funakoshi T, Kameyama K, Amagai M, Kubo A, Umegaki-Arao N. Azathioprine-induced alopecia and leukopenia associated with NUDT15 polymorphisms. J Eur Acad Dermatol Venereol 2018; 32:e386-e389. [PMID: 29704867 DOI: 10.1111/jdv.15028] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- H Nomura
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Y Kurihara
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - M Saito
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - A Fukushima
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - Y Shintani
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - R Shiiyama
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - S Toshima
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - A Kamata
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - J Yamagami
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - T Funakoshi
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - K Kameyama
- Division of Diagnostic Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - M Amagai
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - A Kubo
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| | - N Umegaki-Arao
- Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
| |
Collapse
|
15
|
Bendiab E, Hantaz S, Valentine F, Borlot F, Ramdani M, Suma C, Kubo A, Gaume M, Teron B, Thibaud JC, Oziol E. Polyarthrite aiguë rapidement destructrice avec panniculite : le syndrome PPP. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.03.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
16
|
Yasuda-Sekiguchi F, Shiohama A, Kawasaki H, Ebihara T, Kubo A, Amagai M, Sasaki T. 404 Genetic variants in TLR1, TIRAP and PSAPL1 are enriched in a specific subgroup of adult atopic dermatitis showing persistent skin manifestation on the face and neck area. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
17
|
Fujita H, Sasaki T, Miyamoto T, Mori T, Nakabayashi K, Hata K, Matsuura S, Matsubara Y, Amagai M, Kubo A. 733 Identification and molecular characterization of a CDC20 mutation in a novel mosaic variegated aneuploidy syndrome with premature aging phenotypes. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
18
|
Takahashi H, Nomura H, Iriki H, Kubo A, Mukai M, Sasaki T, Mikami Y, O'Shea J, Amagai M. 013 Cholesterol 25-hydroxylase expressing CD4+ T cell regulates skin inflammation. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
19
|
Takahashi S, Ishida A, Kawasaki H, Kubo A, Amagai M, Okada T. 701 Imaging of the epidermal nerve dynamics and activity in the normal and pruritic dermatitis conditions. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
20
|
Sato M, Uematsu M, Hama Y, Kondo M, Kutsuki S, Shigematsu N, Ando Y, Kusano S, Kubo A. Low-Dose Induction Radiotherapy for Stomach Conservation in Patients with Massive Gastric Lymphoma. Tumori 2018; 86:286-8. [PMID: 11016705 DOI: 10.1177/030089160008600405] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Low-dose induction radiotherapy was performed in 4 patients with massive gastric lymphoma in order to treat the disease without gastrectomy. Following the radiotherapy, gastric lesions had shrunk considerably without any complications. Standard chemotherapy and/or radiotherapy could then be performed safely, and stomach conservation could be achieved in all 4 patients.
Collapse
Affiliation(s)
- M Sato
- Radiation Oncology, Keio University School of Medicine, Shinjuku, Tokyo, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Horikawa H, Kurihara Y, Funakoshi T, Umegaki-Arao N, Takahashi H, Kubo A, Tanikawa A, Kodani N, Minami Y, Meguro S, Itoh H, Izumi K, Nishie W, Shimizu H, Amagai M, Yamagami J. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol 2018; 178:1462-1463. [PMID: 29478242 DOI: 10.1111/bjd.16479] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- H Horikawa
- Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - Y Kurihara
- Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - T Funakoshi
- Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - N Umegaki-Arao
- Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - H Takahashi
- Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - A Kubo
- Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - A Tanikawa
- Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - N Kodani
- Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.,Center for Preventative Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - Y Minami
- Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - S Meguro
- Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - H Itoh
- Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - K Izumi
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan
| | - W Nishie
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan
| | - H Shimizu
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan
| | - M Amagai
- Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - J Yamagami
- Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| |
Collapse
|
22
|
Kubo A, Atsugi T, Yokouchi M, Hirabayashi A, Ohyama M, Amagai M. 245 Tight junction barriers in sebaceous glands are crucial for proper terminal differentiation of sebocytes. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
23
|
Goto S, Kubo A, Hattori K, Yoshioka T, Kajimura M, Suematsu M. A method enabling quantitative intergroup comparison of local metabolites, reveals ATP elevation in the peri-core region upon focal ischemia. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Kawanaka T, Furutani S, Kubo A, Tonoiso C, Ikushima H, Harada M. Low-Dose Rate Brachytherapy with I-125 Seeds as a Monotherapy for High-Risk Prostate Cancer Patient: A Japanese Single Institutional Study. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Lewis J, Caldara A, Strong N, Wahl J, Mattheyses A, Amagai M, Sasaki T, Nakabayashi K, Hata K, Matsubara Y, Kubo A, Stahley S, Kowalczyk A. 544 A mutation in the desmoglein 1 transmembrane domain abrogates lipid raft targeting and causes severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Kinoshita‐Ise M, Kubo A, Sasaki T, Umegaki‐Arao N, Amagai M, Ohyama M. Identification of factors contributing to phenotypic divergence via quantitative image analyses of autosomal recessive woolly hair/hypotrichosis with homozygous c.736T>A
LIPH
mutation. Br J Dermatol 2016; 176:138-144. [DOI: 10.1111/bjd.14836] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/22/2016] [Indexed: 11/27/2022]
Affiliation(s)
- M. Kinoshita‐Ise
- Department of Dermatology Keio University School of Medicine Tokyo Japan
- Department of Dermatology Kyorin University School of Medicine Tokyo Japan
| | - A. Kubo
- Department of Dermatology Keio University School of Medicine Tokyo Japan
| | - T. Sasaki
- Department of Dermatology Keio University School of Medicine Tokyo Japan
- KOSÉ Endowed Program for Skin Care and Allergy Prevention Keio University School of Medicine Tokyo Japan
| | - N. Umegaki‐Arao
- Department of Dermatology Keio University School of Medicine Tokyo Japan
| | - M. Amagai
- Department of Dermatology Keio University School of Medicine Tokyo Japan
| | - M. Ohyama
- Department of Dermatology Keio University School of Medicine Tokyo Japan
- Department of Dermatology Kyorin University School of Medicine Tokyo Japan
| |
Collapse
|
27
|
Kumagai Y, Umegaki-Arao N, Sasaki T, Nakamura Y, Takahashi H, Ashida A, Tsunemi Y, Kawashima M, Shimizu A, Ishiko A, Nakamura K, Tsuchihashi H, Amagai M, Kubo A. Distinct phenotype of epidermolysis bullosa simplex with infantile migratory circinate erythema due to frameshift mutations in the V2 domain of KRT5. J Eur Acad Dermatol Venereol 2016; 31:e241-e243. [DOI: 10.1111/jdv.14005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Y. Kumagai
- Department of Dermatology; Keio University School of Medicine; Tokyo Japan
| | - N. Umegaki-Arao
- Department of Dermatology; Keio University School of Medicine; Tokyo Japan
| | - T. Sasaki
- Department of Dermatology; Keio University School of Medicine; Tokyo Japan
- KOSE Endowed Program for Skin Care and Allergy Prevention; Keio University School of Medicine; Tokyo Japan
| | - Y. Nakamura
- Department of Dermatology; Keio University School of Medicine; Tokyo Japan
| | - H. Takahashi
- Department of Dermatology; Keio University School of Medicine; Tokyo Japan
| | - A. Ashida
- Department of Dermatology; Shinshu University School of Medicine; Nagano Japan
| | - Y. Tsunemi
- Department of Dermatology; Tokyo Women's Medical University; Tokyo Japan
| | - M. Kawashima
- Department of Dermatology; Tokyo Women's Medical University; Tokyo Japan
| | - A. Shimizu
- Department of Dermatology; School of Medicine; Faculty of Medicine; Toho University; Tokyo Japan
| | - A. Ishiko
- Department of Dermatology; School of Medicine; Faculty of Medicine; Toho University; Tokyo Japan
| | - K. Nakamura
- Department of Dermatology; Saitama Medical University; Saitama Japan
| | - H. Tsuchihashi
- Department of Dermatology; Saitama Medical University; Saitama Japan
| | - M. Amagai
- Department of Dermatology; Keio University School of Medicine; Tokyo Japan
- KOSE Endowed Program for Skin Care and Allergy Prevention; Keio University School of Medicine; Tokyo Japan
| | - A. Kubo
- Department of Dermatology; Keio University School of Medicine; Tokyo Japan
| |
Collapse
|
28
|
Takahashi H, Nomura H, Iriki H, Mikami Y, Kanno Y, Kubo A, O’Shea J, Amagai M. 242 Novel immune regulation by CD4 + T cells via cholesterol 25-hydroxylase pathway. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
29
|
Rübsam M, Mertz A, Kubo A, Dufresne E, Horsley V, Ziegler W, Wickström S, Amagai M, Niessen C. 143 E-cadherin integrates EGFR signaling and mechanotransduction to control tissue polarization and barrier formation. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Ruebsam M, Mertz A, Goranci G, Horsley V, Dufresne E, Ziegler W, Kubo A, Amagai M, Niessen C. 430 Tissue polarization of mechano-adhesive signals, cytoskeleton and EGFR signaling controls skin barrier formation. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Ichiyama S, Funasaka Y, Otsuka Y, Takayama R, Kawana S, Saeki H, Kubo A. Effective treatment by glycolic acid peeling for cutaneous manifestation of familial generalized acanthosis nigricans caused by FGFR3 mutation. J Eur Acad Dermatol Venereol 2016; 30:442-5. [PMID: 26818779 DOI: 10.1111/jdv.13580] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 11/27/2015] [Indexed: 12/21/2022]
Abstract
BACKGROUND Acanthosis nigricans (AN) can occur as a cutaneous manifestation of genetic diseases, one of which is associated with activating mutations of the fibroblast growth factor receptor 3 gene (FGFR3). OBJECTIVE We explored familial AN patients with FGFR3 mutations and examined the effectiveness of glycolic acid (GA) peeling in improving their skin manifestations. METHODS Sanger sequencing was performed for the genomic DNA extracted from leucocytes of the family members involving familial AN. GA peeling was carried out for the two patients of familial AN once every 2 weeks. RESULTS Heterozygous c.1949A>C (p.K650T) mutation in FGFR3 was identified for the affected family members examined, whereas the wild-type sequence was found for two unaffected individuals. Hyperpigmentation and coarseness of the skin were improved by GA peeling at regular intervals with few adverse effects. CONCLUSION We diagnosed our cases as familial generalized AN caused by heterozygous c.1949A>C (p.K650T) mutation of FGFR3. We propose that GA peeling is a useful and safe therapeutic option to treat familial AN.
Collapse
Affiliation(s)
- S Ichiyama
- Department of Dermatology, Nippon Medical School Hospital, Tokyo, Japan
| | - Y Funasaka
- Department of Dermatology, Nippon Medical School Hospital, Tokyo, Japan
| | - Y Otsuka
- Department of Dermatology, Nippon Medical School Hospital, Tokyo, Japan
| | - R Takayama
- Department of Dermatology, Nippon Medical School Hospital, Tokyo, Japan
| | - S Kawana
- Department of Dermatology, Nippon Medical School Hospital, Tokyo, Japan
| | - H Saeki
- Department of Dermatology, Nippon Medical School Hospital, Tokyo, Japan
| | - A Kubo
- Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
32
|
Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 2015; 42:279-90. [PMID: 26111727 DOI: 10.1111/nan.12259] [Citation(s) in RCA: 145] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Accepted: 06/21/2015] [Indexed: 12/12/2022]
Abstract
AIMS Primary central nervous system lymphoma (PCNSL) manifest aggressive clinical behaviour and have poor prognosis. Although constitutive activation of the nuclear factor-κB (NF-κB) pathway has been documented, knowledge about the genetic alterations leading to the impairment of the NF-κB pathway in PCNSLs is still limited. This study was aimed to unravel the underlying genetic profiles of PCNSL. METHODS We conducted the systematic sequencing of 21 genes relevant to the NF-κB signalling network for 71 PCNSLs as well as the pyrosequencing of CD79B and MYD88 mutation hotspots in a further 35 PCNSLs and 46 glioblastomas (GBMs) for validation. RESULTS The results showed that 68 out of 71 PCNSLs had mutations in the NF-κB gene network, most commonly affecting CD79B (83%), MYD88 (76%), TBL1XR1 (23%), PRDM1 (20%) and CREBBP1 (20%). These mutations, particularly CD79B and MYD88, frequently coincided within each tumour in various combinations, simultaneously affecting diverse pathways within the network. No GBMs had hotspot mutation of CD79B Y196 and MYD88 L265. CONCLUSIONS The prevalence of CD79B and MYD88 mutations in PCNSLs was considerably higher than reported in systemic diffuse large B-cell lymphomas. This observation could reflect the paucity of antigen stimuli from the immune system in the central nervous system (CNS) and the necessity to substitute them by the constitutive activation of CD79B and MYD88 that would initiate the signalling cascades. These hotspot mutations may serve as a genetic hallmark for PCNSL serving as a genetic marker for diagnose and potential targets for molecular therapy.
Collapse
Affiliation(s)
- T Nakamura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | - K Tateishi
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | - T Niwa
- Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan
| | - Y Matsushita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - K Tamura
- Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - M Kinoshita
- Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - K Tanaka
- Department of Neurosurgery, Graduate School of Medicine, Kobe University, Kobe, Japan
| | - S Fukushima
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - H Takami
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - H Arita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - A Kubo
- Department of Neurosurgery, Yokosuka Kyosai Hospital, Yokosuka, Japan
| | - T Shuto
- Department of Neurosurgery, Yokohama Rosai Hospital, Yokohama, Japan
| | - M Ohno
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - Y Miyakita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - S Kocialkowski
- Department of Pathology, University of Cambridge, Cambridge, UK
| | - T Sasayama
- Department of Neurosurgery, Graduate School of Medicine, Kobe University, Kobe, Japan
| | - N Hashimoto
- Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - T Maehara
- Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - S Shibui
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - T Ushijima
- Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan
| | - N Kawahara
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | - Y Narita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - K Ichimura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| |
Collapse
|
33
|
Ohsugi H, Murata S, Kubo A, Hachiya M, Hirao A, Fujiwara K, Kamijou K. The involvement of attentional function in the scoring of the 30-second chair stand test. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.2029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Goto K, Kubo A, Kouzu N. Measurement of site-specific muscle mass in ambulatory elderly patients to determine levels of activity. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Miyachi R, Yamazaki T, Kubo A. Effects of static interventions on disuse atrophy of rat soleus muscle depend on the longitudinal sites. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Han H, Kubo A, Maruichi S, Sadakiyo K, Kurosawa K. Correlation coefficient investigation of the classification of the difference patterns of ipsilateral hip rotational range of motion. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
37
|
Kubo A, Ikushima H, Kawanaka T, Furutani S, Masafumi H. Contribution of Imaging in Diagnosis of Local Recurrence After Radiation Therapy for Cervical Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
38
|
Hayashi G, Shibato J, Imanaka T, Cho K, Kubo A, Kikuchi S, Satoh K, Kimura S, Ozawa S, Fukutani S, Endo S, Ichikawa K, Agrawal GK, Shioda S, Fukumoto M, Rakwal R. Unraveling Low-Level Gamma Radiation-Responsive Changes in Expression of Early and Late Genes in Leaves of Rice Seedlings at litate Village, Fukushima. J Hered 2014; 105:723-38. [DOI: 10.1093/jhered/esu025] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
|
39
|
Yokoe N, Kubo A, Kosaka K, Hamanaka R, Matsubara A, Nishimura M, Tanaka H, Asai N, Takahashi A, Yamaguchi E. Interstitial Lung Disease (ILD) After Pleurodesis Against Malignant Pleural Effusion (MPE). Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Ohno A, Hirashima T, Kubo A, Masuda N, Takada M, Fujiwara H, Yasumitsu T, Kikui M, Fukuoka M, Nakagawa K. p53 status and prognosis in stage I-IIIa non-small cell lung cancer. Int J Oncol 2012; 10:521-8. [PMID: 21533407 DOI: 10.3892/ijo.10.3.521] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
To investigate the role of p53 abnormalities in predicting the survival of patients with non-small cell lung cancer (NSCLC), polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and immunohistochemical analyses were performed on 74 and 67 tumor samples, respectively, from patients with pathological stage I-IIIa NSCLC. An abnormally migrating SSCP band was observed in 21 of 74 (28%) tumor specimens. DNA sequence analysis revealed 23 intragenic mutations including 3 small deletions and 20 point mutations. Immunohistochemical analysis using the DO-7 monoclonal antibody showed abnormal expression of p53 in 27 of 67 (40%) patients. The concordance rate between immunohistochemical and PCRSSCP analyses was 73% (49/67) in this study. Univariate and multivariate analyses demonstrated that abnormal expression of p53 may be associated with prolonged survival (p=0.0997 and 0.0099, respectively). In contrast, no relationship was observed between p53 mutation and overall survival (0.6968). These results suggest that p53 status and the survival outcome changes between immunohistochemical and mutational analyses in stage I-IIIa NSCLC.
Collapse
Affiliation(s)
- A Ohno
- KINKI UNIV,SCH MED,DEPT INTERNAL MED 4,OSAKA,OSAKA 589,JAPAN. GIFU UNIV,SCH MED,DEPT INTERNAL MED 2,GIFU 500,JAPAN. OSAKA PREFECTURE HABIKINO HOSP,DEPT INTERNAL MED,HABIKINO,OSAKA 583,JAPAN. OSAKA PREFECTURE HABIKINO HOSP,DEPT SURG,HABIKINO,OSAKA 583,JAPAN. OSAKA PREFECTURE HABIKINO HOSP,DEPT PATHOL,HABIKINO,OSAKA 583,JAPAN
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Kubo A, Kanaji N, Bandoh S, Ishii T, Fujita J, Matsunaga T, Yamaguchi E. Cytokeratin (CK) 8 Expression in Non-Small-Cell Lung Cancer (NSCLC) and its Relation to Tumor Invasiveness and Patient Survival. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32263-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
42
|
Omachi N, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, Asami K, Okishio K, Atagi S, Okuma T, Kubo A, Maruyama Y, Kudoh S, Takada M, Nishie K. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32323-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
43
|
Tsujino K, Shiraishi J, Tsuji T, Kurata T, Kawaguchi T, Kubo A, Takada M. Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer? Ann Oncol 2010; 21:1668-1674. [DOI: 10.1093/annonc/mdp588] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
44
|
Kawaguchi T, Ando M, Kubo A, Takada M, Atagi S, Okishio K, Asami K, Matsumura A, Tsujino K, Sasaki H. Association of gender and passive smoking with epidermal growth factor receptor mutations in never-smokers with non-small cell lung cancer: A prospective study based on detailed passive smoking questionnaire. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Hasegawa Y, Kawaguchi T, Kubo A, Ando M, Shiraishi J, Isa S, Tsuji T, Tsujino K, Nakagawa K, Takada M. Ethnic difference in toxicity in non-small cell lung cancer patients treated with chemotherapy: A systematic review on phase II and III clinical trials. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Kubo A, Koh Y, Hori T, Isa S, Fukuoka J, Kawaguchi T, Masahiko A, Okamoto I, Kitaichi M, Takada M. Pharmacokinetic, pharmacodynamic, and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Koshiba H, Hosokawa K, Kubo A, Miyagi Y, Oda T, Miyagi Y, Watanabe A, Honjo H. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int J Gynecol Cancer 2009; 19:460-5. [PMID: 19407575 DOI: 10.1111/igc.0b013e3181a1bf2e] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Carboplatin is one of the most commonly used and well-tolerated agents for gynecologic malignancies. The rate of hypersensitivity reactions (HSRs) in the overall population of patients receiving carboplatin has been reported to increase after multiple doses of the agent. We retrospectively analyzed the incidence, clinical features, management, or outcome of carboplatin-related HSRs in 113 Japanese patients with gynecologic malignancies and the possibility of rechallenge with the drug. We intravenously administered carboplatin after paclitaxel or docetaxel. Mild HSRs are resolved by temporary interruption of carboplatin infusion, an additional antihistamine, and/or a corticosteroid. If HSRs arose, carboplatin was diluted, not exceeding 1 mg/mL, and slowly infused over 2 hours in subsequent cycles. Ten patients experienced carboplatin HSRs, with an overall incidence of 8.85%. The first HSR episode was mild in all cases. When retreated with carboplatin, 4 exhibited severe HSRs. More than 9 cycles and/or more than 5000 mg of carboplatin administration significantly increased the incidence of HSRs. In particular, carboplatin treatment beyond 15 cycles and/or 8000 mg increased the risk of severe HSRs (P < 0.0001). The incidence of HSRs in the ovarian carcinoma group was significantly greater than that in the uterine carcinoma group (P = 0.0046). Careful attention should be paid to HSRs during carboplatin treatment beyond 9 cycles and/or 5000 mg. The rate of severe HSRs greatly increases beyond 15 cycles and/or 8000 mg. Further studies are needed to identify potential risk factors that may contribute to the development of carboplatin HSRs and to decrease the risk of reactions.
Collapse
Affiliation(s)
- H Koshiba
- Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kajiicho, Kamigyoku, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Asami K, Kawahara M, Atagi S, Kawaguchi T, Kubo A, Okishio K, Yagi Y, Matsuda Y, Kagawa T, Kitaichi M. Influence of smoking dose on the outcome of Japanse patients with non-small cell lung cancer who had gefitinib treatment. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19004 Background: Non-smoking history and epidermal growth factor receptor (EGFR) mutation are associated with increased sensitivity to gefitinib in non-small cell lung cancer (NSCLC). However, it is still unclear how much smoking dose is associated with survival and response to gefitinib among smokers. Methods: NSCLC patients (pts) with detailed smoking history who received gefitinib at our institution between 9/02 and 9/04 were reviewed. An analysis was conducted to the pts for association between smoking dose, EGFR mutations, performance status (PS), response and overall survival using multivariate analysis. Results: Data were available for 100 pts including 30 females and 70males. We expressed smoking dose as pack year (Py).The median dose of smoking was 32 Py (0.1–100 Py). We defined the group of <10 Py as light smokers(17 pts) and the other group of 10 Py or more as heavy smokers(83 pts). We detected 31(31%) EGFR mutation (median 14 Py 0.1–75 Py) with exon 18 / 19 /21 mutation;3/17/11 pts .Cox survival analysis showed that overall survival was preferably associated with small dose of smoking(<10 Py)(HR=0.505; [95% CI 0.277–0.921; P=0.013]), EGFR mutation(HR=0.452[95% CI 0.235–0.87;P=0.035])and PS;0–1(HR=0.347 [95% CI 0.207–0.583 P<0.001]). EGFR mutations were significantly more frequently observed in light (12/17:71%) than heavy smokers(19/83:23%) (p<0.001). Disease control rate(DCR) was significantly higher in light (13/17;76%;PR 6, SD 7) than heavy smokers(29/83;35%;PR 15, SD 14)(P=0.002), but there was not significant difference between those groups in terms of response rate (RR)(P=0.187). There were significant differences between pts with EGFR mutations (PR 13 SD 14; RR 42%,DCR 87%) and pts without EGFR mutations (PR 8 SD 15; RR 12%, DCR 33%) in terms of RR(P<0.001) and DCR(P<0.001). In pts with EGFR mutation, there was no significant difference between light and heavy smokers in terms of RR (light smokers 5/10, heavy smokers 8/21; P=0.701) and DCR (light smokers 10/10, heavy smokers17/21; P= 0.277). Conclusions: EGFR mutations were predictive factor and prognostic factor. Small dose of smoking (< 10 Py) was prognostic factor, however it was not a predictive factor of smokers with NSCLC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Asami
- Kinki Chest Medical Center, Sakai, Japan
| | | | - S. Atagi
- Kinki Chest Medical Center, Sakai, Japan
| | | | - A. Kubo
- Kinki Chest Medical Center, Sakai, Japan
| | - K. Okishio
- Kinki Chest Medical Center, Sakai, Japan
| | - Y. Yagi
- Kinki Chest Medical Center, Sakai, Japan
| | - Y. Matsuda
- Kinki Chest Medical Center, Sakai, Japan
| | - T. Kagawa
- Kinki Chest Medical Center, Sakai, Japan
| | | |
Collapse
|
49
|
Satouchi M, Yamamoto N, Chiba Y, Kudoh S, Hida T, Kubo A, Seto T, Nishimura Y, Nakagawa K, Fukuoka M. Randomized, phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small cell lung cancer (NSCLC): WJTOG0105. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7504] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7504 Background: Weekly chemotherapy with concurrent TRT displays acceptable toxicities and dependable efficacy. We conducted a randomized phase III trial to assess the efficacy and toxicity of weekly chemotherapy with concurrent TRT against MVP with concurrent TRT via a non-inferiority design. Methods: MVP: mitomycin (8 mg/m2 on days 1, 29), vindesine (3 mg/m2 on days 1, 8, 29, 36), and cisplatin (80 mg/m2 on days 1, 29) with concurrent TRT (60 Gy). Patients (pts) subsequently received 2 courses of consolidation chemotherapy with MVP; IC: weekly irinotecan (20 mg/m2)/carboplatin (AUC 2) for 6 weeks and TRT (60 Gy) followed by 2 courses of irinotecan (50 mg/m2)/carboplatin (AUC 5); PC: weekly paclitaxel (40 mg/m2)/carboplatin (AUC 2) for 6 weeks and TRT (60 Gy) followed by 2 courses of paclitaxel (200 mg/m2)/carboplatin (AUC 5). The primary endpoint was overall survival (OS), with secondary endpoints of progression free survival (PFS), response, and toxicity. Results: From Sep 2001 to Sep 2005, 456 pts were randomized. Pretreatment characteristics were well-balanced among 3 arms. Major toxicity incidences: The incidence of G3–4 neutropenia in the MVP, IC, and PC arms was 95.9, 72.1, and 46.9 % (p<0.001). The G3–4 non-hematologic toxicity incidences in terms of fatigue, febrile neutropenia, and gastrointestinal disorder were 13.0, 6.1, and 4.8 % (p<0.001), 37.0, 8.8, and 10.2 % (p<0.001), and 24.0, 8.2, and 9.5% (p<0.001) in the respective arms. The overall response rates were 66.4, 56.5, and 63.3 %, in the MVP, IC and PC arms, respectively. The median survival times were 20.5, 19.8 and 22.0 months and the median PFS (MPFS), 8.2, 8.0 and 9.5 months in MVP, IC and PC. Non-inferiority of the 2 experimental arms compared with MVP was not achieved, though no significant differences in OS and PFS were apparent among treatments. The PC arm displayed the most favorable MST, MPFS, and hematologic/non-hematologic toxicities. Conclusions: Weekly PC with TRT displays similar efficacy and more favorable toxicity profiles compared to MVP with TRT. Weekly PC with TRT warrants use as the reference regimen in forthcoming studies. [Table: see text]
Collapse
Affiliation(s)
- M. Satouchi
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| | - N. Yamamoto
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| | - Y. Chiba
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| | - S. Kudoh
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| | - T. Hida
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| | - A. Kubo
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| | - T. Seto
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| | - Y. Nishimura
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| | - K. Nakagawa
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| | - M. Fukuoka
- Hyogo Cancer Center, Akashi, Japan; Shizuoka Cancer Center, Naga-izumi, Japan; Kinki University School of Medicine, Osaka-Sayama, Japan; Osaka City University Msdical School, Osaka, Japan; Aichi Cancer Center, Nagoya, Japan; Kinki-Chuo Chest Medicial Center, Sakai, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; Kinki University School of Medicine, Sakai Hospital, Sakai, Japan; West Japan Oncology Group (WJOG)
| |
Collapse
|
50
|
Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Quesenberry C, Buffler P. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009; 58:182-8. [PMID: 18978173 PMCID: PMC2671084 DOI: 10.1136/gut.2008.163360] [Citation(s) in RCA: 122] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE To evaluate the demographics and incidence of Barrett's oesophagus diagnosis using community-based data. DESIGN Observational study. SETTING Kaiser Permanente, Northern California healthcare membership, 1994-2006. PATIENTS Members with an electronic diagnosis of Barrett's oesophagus. MAIN OUTCOME MEASURES Incidence and prevalence of a new Barrett's oesophagus diagnosis by race, sex, age and calendar year. RESULTS 4205 persons met the study definition for a diagnosis of Barrett's oesophagus. The annual incidence in 2006 was highest among non-Hispanic whites (39/100,000 race-specific member-years, 95% confidence interval (95% CI) 35 to 43), with lower rates among Hispanics (22/100,000, 95% CI 16 to 29), Asians (16/100,000, 95% CI 11 to 22), and blacks (6/100,000, 95% CI 2 to 12). The annual incidence was higher among men than women (31 vs 17/100,000, respectively, year 2006; p<0.01). The incidence increased with age from 2 per 100,000 for persons aged 21-30 years, to a peak of 31 per 100,000 member-years for persons aged 61-70 years (year 2006). There was no increase in the incidence of new diagnoses until the last two observation years, which coincided with changes in data collection methods and may be due to bias. The overall prevalence among active members increased almost linearly to 131/100,000 member-years by 2006. CONCLUSIONS The demographic distributions of Barrett's oesophagus differ markedly by race, age and sex and were comparable to those for oesophageal adenocarcinoma. Thus, demographic disparities in oesophageal adenocarcinoma risk may arise partly from the risk of having Barrett's oesophagus, rather than from differing risks of progression from Barrett's oesophagus to cancer. There has been an almost linear increase in the prevalence of diagnosed disease.
Collapse
Affiliation(s)
- D A Corley
- Division of Research, Kaiser Permanente, Oakland, CA 94612, USA.
| | - A Kubo
- Division of Research, Kaiser Permanente, Oakland, California, USA
| | - T R Levin
- Division of Research, Kaiser Permanente, Oakland, California, USA
| | - G Block
- School of Public Health University of California, Berkeley, California, USA
| | - L Habel
- Division of Research, Kaiser Permanente, Oakland, California, USA
| | - G Rumore
- Kaiser Permanente, Oakland Medical Center, Oakland, California, USA
| | - C Quesenberry
- Division of Research, Kaiser Permanente, Oakland, California, USA
| | - P Buffler
- School of Public Health University of California, Berkeley, California, USA
| |
Collapse
|